Karyopharm Therapeutics Inc. (KPTI)

Profile

https://www.karyopharm.com

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing therapies for cancer and other serious diseases. Karyopharm Therapeutics Inc. specializes in drugs that target nuclear export pathways, including selective inhibitor of nuclear export compounds designed to inhibit exportin 1 (XPO1). Its current portfolio centers on oncology, with marketed and late-stage programs addressing blood cancers and solid tumors. The company’s products and clinical development efforts are aimed at treating patients who need options across hematology and oncology settings, and its commercial activities support the availability of approved cancer therapies in the United States. Headquartered in Newton, Massachusetts, Karyopharm Therapeutics Inc. plays a specialized role in the biopharmaceutical market by advancing targeted treatments built around a distinct molecular mechanism.